| Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians S Lillioja, DM Mott, M Spraul, R Ferraro, JE Foley, E Ravussin, ... New England Journal of Medicine 329 (27), 1988-1992, 1993 | 2050 | 1993 |
| Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance C Weyer, JE Foley, C Bogardus, PA Tataranni, RE Pratley Diabetologia 43, 1498-1506, 2000 | 1013 | 2000 |
| A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM G Paolisso, PA Tataranni, JE Foley, C Bogardus, BV Howard, E Ravussin Diabetologia 38, 1213-1217, 1995 | 528 | 1995 |
| Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1year B Ahren, G Pacini, JE Foley, A Schweizer Diabetes care 28 (8), 1936-1940, 2005 | 485 | 2005 |
| Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes A Mari, WM Sallas, YL He, C Watson, M Ligueros-Saylan, BE Dunning, ... The Journal of Clinical Endocrinology & Metabolism 90 (8), 4888-4894, 2005 | 483 | 2005 |
| Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes N Matikainen, S Mänttäri, A Schweizer, A Ulvestad, D Mills, BE Dunning, ... Diabetologia 49, 2049-2057, 2006 | 444 | 2006 |
| Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes A Schweizer, A Couturier, JE Foley, S Dejager Diabetic Medicine 24 (9), 955-961, 2007 | 386 | 2007 |
| Alpha cell function in health and disease: influence of glucagon-like peptide-1 BE Dunning, JE Foley, B Ahrén Diabetologia 48, 1700-1713, 2005 | 365 | 2005 |
| Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea AJ Garber, JE Foley, MA Banerji, P Ebeling, S Gudbjörnsdottir, ... Diabetes, Obesity and Metabolism 10 (11), 1047-1056, 2008 | 354 | 2008 |
| In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. A Kashiwagi, MA Verso, J Andrews, B Vasquez, GM Reaven, JE Foley The Journal of clinical investigation 72 (4), 1246-1254, 1983 | 338 | 1983 |
| Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. ES Horton, C Clinkingbeard, M Gatlin, J Foley, S Mallows, S Shen Diabetes care 23 (11), 1660-1665, 2000 | 337 | 2000 |
| Kinetics of glucose disposal in whole body and across the forearm in man. H Yki-Järvinen, AA Young, C Lamkin, JE Foley The Journal of clinical investigation 79 (6), 1713-1719, 1987 | 328 | 1987 |
| Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response S Ristic, S Byiers, J Foley, D Holmes Diabetes, Obesity and Metabolism 7 (6), 692-698, 2005 | 324 | 2005 |
| The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients B Balas, MR Baig, C Watson, BE Dunning, M Ligueros-Saylan, Y Wang, ... The Journal of Clinical Endocrinology & Metabolism 92 (4), 1249-1255, 2007 | 306 | 2007 |
| Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study DR Matthews, S Dejager, B Ahrén, V Fonseca, E Ferrannini, A Couturier, ... Diabetes, Obesity and Metabolism 12 (9), 780-789, 2010 | 303 | 2010 |
| Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study S Dejager, S Razac, JE Foley, A Schweizer Hormone and metabolic research 39 (03), 218-223, 2007 | 289 | 2007 |
| Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus JE Foley Diabetes Care 15 (6), 773-784, 1992 | 258 | 1992 |
| Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal WJ Andrews, B Vasquez, M Nagulesparan, I Klimes, J Foley, R Unger, ... Diabetes 33 (7), 634-642, 1984 | 256 | 1984 |
| Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes B Ahrén, A Schweizer, S Dejager, BE Dunning, PM Nilsson, M Persson, ... The Journal of Clinical Endocrinology & Metabolism 94 (4), 1236-1243, 2009 | 250 | 2009 |
| Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population A Schweizer, S Dejager, JE Foley, A Couturier, M Ligueros‐Saylan, ... Diabetes, Obesity and Metabolism 12 (6), 485-494, 2010 | 236 | 2010 |
Jens Juul HolstProfessor of Medical Physiology, University of CopenhagenEmail confirmado em sund.ku.dk
